Related Experiment Videos
Systemic lupus erythematosus presenting with myelofibrosis
D Foley-Nolan1, M F Martin, D Rowbotham
1St. James's University Hospital, Leeds, UK.
The Journal of Rheumatology
|August 1, 1992
Summary
Myelofibrosis can complicate systemic lupus erythematosus (SLE), sometimes resisting initial corticosteroid treatment. Combination therapy with steroids and azathioprine achieved remission in a challenging case.
Area of Science:
- Hematology
- Rheumatology
- Internal Medicine
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations.
- Myelofibrosis is a serious bone marrow disorder characterized by fibrosis and impaired hematopoiesis.
- The interplay between SLE and myelofibrosis is not fully understood, posing diagnostic and therapeutic challenges.
Observation:
- A 20-year-old female presented with concurrent myelofibrosis and SLE.
- Initial treatment with corticosteroids led to temporary improvement, but a relapse showed persistent myelofibrosis.
- Bone marrow biopsy confirmed lack of improvement despite prior treatment.
Findings:
- Severe SLE treatments can cause bone marrow suppression, mimicking or exacerbating myelofibrosis.
- Myelofibrosis complicating SLE may not respond effectively to corticosteroids alone.
- High-dose steroids combined with azathioprine successfully induced remission of myelofibrosis in this patient.
Implications:
- Highlights the importance of considering myelofibrosis in SLE patients, especially during relapses or treatment failures.
- Suggests that aggressive immunosuppressive therapy, including azathioprine, may be beneficial for myelofibrosis in the context of SLE.
- Underscores the need for careful monitoring of bone marrow function in SLE patients undergoing cytotoxic therapy.